 Secondary Objective: To detect and quantitate immune responses induced by the proposed peptide vaccine or protein vaccine in association with CpG 7909 and cyclophosphamide. This endpoint will be assessed by an IFN-y ELISPOT assay of NY-ESO-1-specific tumor-reactive CD8 T cells. We also will look for NY-ESO-1 tetramer CD8 T cells, Delayed-type Hypersensitivity DTH, and NY-ESO-1-specific CD4 T cell responses with ELISPOT assays and cytokine-release-assays. 